期刊文献+

Inhibition of RNaseH2A Induces Fas-Regulated Programmed Cell Death in Hepatoma Cells

下载PDF
导出
摘要 Objective:To screen clinically significant potential drug targets in liver cancer and to study the function and potential molecular mechanisms of this target protein in the development of liver cancer.Methods:By using the clinical database GEPIAto find genes that are differentially expressed in liver cancer compared to normal tissues,we further screened the genes that are highly expressed in hepatocellular carcinoma and have clinical prognostic relevance.Heat maps were used to sort these genes according to their clinical prognostic relevance,so as to screen for the target gene of interest.The characteristics of target gene expression and clinical prognosis in hepatocellular carcinoma were studied.The target gene was knocked down through siRNA,and cell proliferation experiments and apoptosis experiments were used to verify the importance of the target gene in the occurrence and development of liver cancer.Finally,we elucidated the potential molecular mechanism of the target gene's function in liver cancer based on the mutual regulatory relationship between the target gene and key apoptosis genes.Results:1482 genes were significantly underexpressed in liver cancer,and 725 genes were significantly overexpressed in liver cancer,of which RNaseH2A was significantly overexpressed in liver cancer and had a significant clinical prognosis.Knockdown of RNaseH2A inhibited the proliferation of hepatocellular carcinoma cells and induced apoptosis.Knockdown of RNaseH2A induced the high expression of Fas,a key gene for apoptosis,and liver cancer usually features low expression of Fas.After hepatocellular carcinoma cells that were knocked down of RNaseH2A continued were subject to Fas knockdown,hepatocellular carcinoma cell proliferation and apoptosis returned to normal levels.Conclusion:The high expression of RNaseH2A regulates the low expression of Fas,a key gene for apoptosis,thereby inhibiting apoptosis,promoting cell proliferation,and participating in the development of liver cancer.
出处 《Proceedings of Anticancer Research》 2022年第3期53-62,共10页 抗癌研究
基金 General Special Scientific Research Project of Shaanxi Provincial Department of Education“Molecular Mechanism of MiR-122 Competing Endogenous IncRNA in the Development of Liver Cancer”(Project Number:20JK0887)。
  • 相关文献

参考文献1

二级参考文献175

  • 1El-Serag HB. Epidemiology of viral hepatitis and hepatocellularcarcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID:22537432 DOI: 10.1053/j.gastro.2011.12.061].
  • 2Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK,Selim OE, Badran HM. Prevalence and epidemiological featuresof hepatocellular carcinoma in Egypt-a single center experience.Hepatol Res 2001; 19: 170-179 [PMID: 11164741 DOI: 10.1016/S1386-6346(00)00105-4].
  • 3el-Zayadi AR, Badran HM, Barakat EM, Attia Mel-D, ShawkyS, Mohamed MK, Selim O, Saeid A. Hepatocellular carcinoma inEgypt: a single center study over a decade. World J Gastroenterol2005; 11: 5193-5198 [PMID: 16127751].
  • 4el-Serag HB. Epidemiology of hepatocellular carcinoma. ClinLiver Dis 2001; 5: 87-107, vi [PMID: 11218921 DOI: 10.1016/S1089-3261(05)70155-0].
  • 5Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S,El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A.Changing pattern of hepatitis C virus spread in rural areas of Egypt.J Hepatol 2005; 43: 418-424 [PMID: 16019104 DOI: 10.1016/j.jhep.2005.03.021].
  • 6Strickland GT, Elhefni H, Salman T, Waked I, Abdel-HamidM, Mikhail NN, Esmat G, Fix A. Role of hepatitis C infectionin chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67:436-442 [PMID: 12452500].
  • 7Moradpour D, Blum HE. Pathogenesis of hepatocellularcarcinoma. Eur J Gastroenterol Hepatol 2005; 17: 477-483 [PMID:15827436 DOI: 10.1097/00042737-200505000-00002].
  • 8Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA,Marrero JA. Meta-analysis: surveillance with ultrasound for earlystagehepatocellular carcinoma in patients with cirrhosis. AlimentPharmacol Ther 2009; 30: 37-47 [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x].
  • 9Bruix J, Sherman M. Management of hepatocellular carcinoma: anupdate. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI:10.1002/hep.24199].
  • 10European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTCclinical practice guidelines: management of hepatocellularcarcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI:10.1016/j.jhep.2011.12.001].

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部